This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
Non-Small Cell Lung Cancer
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
-
University of South Alabama; Mitchell Cancer Institute, Mobile, Alabama, United States, 36604
Southern California Kaiser Permanente, San Diego, California, United States, 92108
Rocky Mountain Cancer Centers - Lone Tree, Lone Tree, Colorado, United States, 80124
Mount Sinai Medical Center; Comprehensive Cancer Center, Miami Beach, Florida, United States, 33140
University Of Michigan, Ann Arbor, Michigan, United States, 48109
Oregon Health Sciences Uni, Portland, Oregon, United States, 97239
Northwest Cancer Specialists, P.C., Tigard, Oregon, United States, 97223
Hillman Cancer Center;Medical Oncology, Pittsburgh, Pennsylvania, United States, 15232
Thompson Cancer Survival Center, Knoxville, Tennessee, United States, 37916-2305
Baptist Cancer Center, Memphis, Tennessee, United States, 38120
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Hoffmann-La Roche,
Clinical Trials, STUDY_DIRECTOR, Hoffmann-La Roche
2033-09-01